Invasive mechanical ventilation
The Aerogen Solo vibrating mesh nebuliser delivers aerosol medication to your patients during invasive mechanical ventilation (IMV)1
Closed circuit
Aerogen Solo is a closed-circuit, vibrating mesh nebuliser for aerosol drug delivery1
- Maintains a closed ventilation circuit1,2
- Virtually silent drug delivery,1 keeping a calm environment for your patients
- Eliminates the need to open the circuit when administering medication1,2
Ease of use
The Aerogen Solo vibrating mesh nebuliser simplifies the workflow1
- No added flow1
- One system throughout a patient's respiratory journey (IMV, NIV, HF, SV),1 supporting continuity of care
- The Aerogen Solo vibrating mesh nebuliser is approved for all physician-prescribed medications for inhalation, which are approved for use with a general purpose nebuliser1
†Please refer to 30-354 REV U Aerogen Solo Instruction Manual when using Aerogen
Using Aerogen†
Effectiveness
Aerogen Solo facilitates efficient medication delivery during invasive mechanical ventilation3-5
In studies, aerosol drug delivery with Aerogen Solo was associated with:
- ~4x more drug deposition compared to jet nebulisers†3,‡4
- Higher drug delivery than with a jet nebuliser or a pMDI§5
- <0.1% medication left in the cup after nebulisation versus 56–63% with a jet nebuliser§5
†In-vitro model
‡When placed 15 cm from the Y-piece in a heated setting; in-vitro model
§For both standard and low tidal volume ventilation; in-vitro model
Representative scintigraphic image of aerosol lung deposition in a patient receiving pressure support ventilation (adapted from Dugernier J, et al. Ann Intensive Care. 2016;6(1):73).6
Guidelines
Clinical and scientific societies around the world recommend the use of closed-circuit nebulisers for the management of patients with COVID-19 requiring aerosol drug delivery:
- GOLD: Science Committee Report 20237
- AARC: Guidance 20208
- ISAM: Interim Guidance 20209
- Spanish Scientific Societies: Expert Clinical Consensus 202010
- Chinese Thoracic Society: Respiratory Care Committee 202011
- Indian Society of Critical Care Medicine: Position Statement 202012
- Indian Chest Society: Guidance 202013
Globally renowned
Aerogen technology has been in use for over 25 years, in more than 75 countries globally and is associated with over 200 clinical papers and publications.14 Aerogen is the partner of choice for the world's leading ventilator companies for aerosol drug delivery.14
Enquiries
The Aerogen team and our representatives are available globally to answer your questions, provide an online demonstration and place orders
- 30-354 REV U Aerogen Solo Instruction Manual.
- Joyce M, McGrath JA, Mac Giolla Eain M, et al. Pharmaceutics. 2021;13(2):199.
- Ari A, Atalay OT, Harwood R, et al. Respir Care. 2010;55(7):845-851.
- Ari A, Areabi H, Fink JB. Respir Care. 2010;55(7):837-844.
- Naughton PJ, Joyce M, Mac Giolla Eain M, et al. Pharmaceutics. 2021;13(10):1574.
- Dugernier J, Reychler G, Wittebole X, et al. Ann Intensive Care. 2016;6(1):73.
- Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: 2023 report. Available at: https://goldcopd.org/2023-gold-report-2/ (accessed 06 December 2022).
- American Association for Respiratory Care SARS CoV-2 Guidance Document. https://www.aarc.org/wp-content/
- Fink JB, Ehrmann S, Li J, et al. J Aerosol Med Pulm Drug Deliv. 2020;33(6):300-304.
- Cinesi Gómez C, Peñuelas Rodríguez Ó, Luján Torné M, et al. Med Intensiva (Engl Ed). 2020;44(7):429-438.
- Respiratory care committee of Chinese Thoracic Society. Zhonghua Jie He He Hu Xi Za Zhi. 2020;17(0):E020.
- Kumar S, Mehta S, Sarangdhar N, et al. Expert Rev Respir Med. 2021;15(4):519-535.
- Swarnakar R, Gupta NM, Halder I, et al. Lung India. 2021;38(Supplement):S86-S91.
- Aerogen Data on File.
uploads/2020/03/guidance-document-SARS-COVID19.pdf (accessed 11 Nov 2022).
GL1223B04-23
